(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number
WO 2005/073234 A3

(51) International Patent Classification[7]: C07D 487/04, A61K 31/519

(21) International Application Number: PCT/EP2005/000475

(22) International Filing Date: 19 January 2005 (19.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04002144.6 31 January 2004 (31.01.2004) EP

(71) Applicant *(for all designated States except US)*: **BAYER HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LY, Tai-wei** [JP/JP]; Hill Crest 532-5, 7-chome, Ayameike, Nara-shi, Nara-ken, Nara 631-0033 (JP). **YOSHINO, Takashi** [JP/JP]; Royal Heights Kosei 306, 73 Chuo 5-chome, Kousei-cho Koga-gun, Shiga-ken, Shiga 520-3234 (JP). **TAKEKAWA, Yuki** [JP/JP]; Forest Hosono 103, 14-1 Koaza-Kitarokunotsubo, Oaza-Ueda, Seika-cho, Soraku-gun, Kyoto-fu, Kyoto 619-0236 (JP). **SHINTANI, Takuya** [JP/JP]; 4-24-1, Seikadai, Seika-cho, Soraku-gun, Kyoto-fu, Kyoto 619-0238 (JP). **SUGIMOTO, Hiromi** [JP/JP]; B-201, 4-25-2 Sakuragaoka, Seika-cho, Soraku-gun, Kyoto-fu, Kyoto 619-0232 (JP). **BACON, Kevin B.** [GB/JP]; 5-15-912, Koyo-cho Naka, Higashinada-ku, Kobe-shi, Hyogo-ken, Hyogo 658-0032 (JP). **URBAHNS, Klaus** [DE/JP]; 6-3-1-301, Kusugaoka-cho, Nada-ku, Kobe-shi, Hyogo-ken, Hyogo 657-0024 (JP).

(74) Agent: **RICKER, Mathias**; Jones Day, Prinzregentenstrasse 11, 80538 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report: 6 October 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES

(57) Abstract: The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.

WO 2005/073234 A3